scott@vtx-cpd.com
Forum Replies Created
-
AuthorPosts
-
Replying to Emma Holt 02/07/2024 - 11:02
Hi Emma,
Thank you so much for these really brilliant points! How is maternity leave going?
This was a lab sample sent to an external lab, so it would not be unusual to get mild hypoglycaemia and hyperkalaemia due to transit, such as glucose consumption in transit and potassium increase due to haemolysis.
Your key problem list and DDX are perfect! I think ruling Addison’s out in this case is a great idea. We did run a basal cortisol test which returned at 100 nmol/L. Any result over 55 nmol/L is not consistent with Addison’s, so we were confident this was not the problem in this case. I was less suspicious of Addison’s due to the lymphopenia, but it was a good rule out. I love the possible link between Addison’s and GI bleeding, anaemia, and low albumin too. We can sometimes see increases in potassium due to haemolysis, which is not uncommon in samples transported to the lab. If in doubt, I would run the sample again on a fresh one in-house.
Regarding the possibility of liver disease, for glucose and albumin to decrease there would have to be over 75% liver function loss, which I think is less likely in this case. Albumin can decrease slightly with a negative acute phase response due to infections or inflammatory diseases. Often, globulin will increase in these situations (as it is an acute phase protein), which has not occurred in this case.
In the emergency setting, we did a POCUS scan of the chest and abdomen, and there was no free fluid. The in-saline agglutination was negative, and we examined a blood smear. I have shared the blood smear images below. I would love to hear your thoughts.
Again, great thinking and thank you for your valuable insights!
Best regards,
Scott 🙂
Hello again!
I have some information directly from Zoetis for you too. I will try and upload the documents mentioned too:
“Hi Scott,
I hope you are well and nice to meet you virtually! In regards to Rosanna’s questions, a negative effect on the function of the nervous system would not be an expected adverse effect of either Librela or Solensia. As Rosanna mentions, it is not unusual for some animals with OA to also have pre-existing neurological involvement, however, as the monoclonal antibodies are large molecules, they do not distribute outside of the blood very well and cannot cross into the CNS to any significant effect (in the absence of local severe inflammation such as meningitis). It is also worth noting that Librela and Solensia are also not designed to remove all nerve growth factor (NGF) in the body, only to reduce the elevated levels found in osteoarthritic joints. To give further context to this query, in studies on the human side for anti-NGF mAbs, exhaustive evaluation was conducted for altered sympathetic function and no changes were found.
In terms of what to advise clients in regards to potential adverse effects, the best source of information to share with them is section 4.6 within the respective SPC’s as these list the possible adverse reactions and also guide as to the frequency in which they would be expected. As these are written and amended on a regular basis from on-going pharmacovigilance (PV) and assessment from an independent regulator (the VMD), these form the most reliable guidance when discussing products with owners. Despite both products being licenced since 2021 with millions of doses being given (in excess of 14 million doses for Librela for example), few changes have been made to this section (both SPC’s attached) based on PV reports so hopefully this will give owners confidence and help guide the conversations.
I hope this is helpful but if you have any further queries, please let me know!
Best wishes
Jayne
Jayne Clark BVSc, BSc(Hons), GPCertSAM, MRCVS
Zoetis Veterinary Consultant, East Region”
Replying to Yvonne McGrotty 01/07/2024 - 17:17
Thanks pal.
Scott x
Replying to Ursula Lanigan 23/06/2024 - 22:46
Thanks for sharing!
I totally agree with your approach! I do try and stick to one hydrolysed diet at a time and avoid mixing if possible.
Scott 🙂
Hello everyone!
I hope you are well!
I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.
Radiographic Report:
Findings:
Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
The included cranial abdominal and osseous structures are normal.
Conclusions and Recommendations:Multilobar moderate bronchial to structured interstitial pulmonary pattern.
Right middle lung lobe alveolar pulmonary pattern.
Rightward mediastinal shift.
This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.
This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.
Any thoughts?
Best regards,
Scott 🙂
Hello everyone!
I hope you are well!
I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.
Radiographic Report:
Findings:
Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
The included cranial abdominal and osseous structures are normal.
Conclusions and Recommendations:Multilobar moderate bronchial to structured interstitial pulmonary pattern.
Right middle lung lobe alveolar pulmonary pattern.
Rightward mediastinal shift.
This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.
This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.
Any thoughts?
Best regards,
Scott 🙂
Replying to Ursula Lanigan 23/06/2024 - 22:40
Hello Ursula,
I hope you are well!
I wanted to share the details of a radiographic report for one of my ongoing cases, Fluffy. Based on these findings, I recommended to the owner that we proceed with a CT scan and bronchoscopy, but these were declined at the time.
Radiographic Report:
Findings:
Multifocally throughout the pulmonary parenchyma, there are mild to moderate bronchocentric soft tissue opacities, some of which are slightly nodular in appearance.
In the DV projection, within the right middle lung lobe, there is a region of increased soft tissue opacity that completely silhouettes with the pulmonary vasculature. In the left lateral projection, an air bronchogram is present.
The cardiac silhouette is mildly displaced to the right and is otherwise normal. The pulmonary vasculature and pleural space are normal.
The included cranial abdominal and osseous structures are normal.
Conclusions and Recommendations:Multilobar moderate bronchial to structured interstitial pulmonary pattern.
Right middle lung lobe alveolar pulmonary pattern.
Rightward mediastinal shift.
This constellation of findings is most consistent with inflammatory airway disease. The alveolar pattern in the right middle lung lobe combined with the rightward mediastinal shift may be indicative of lung lobe collapse due to bronchial mucus plugging.Given the area of consolidation observed, I prescribed a two-week course of doxycycline, which seemed to resolve the clinical signs initially. However, these signs have since returned.
This is an ongoing case, and I am currently in discussion with Fluffy’s owners about investigating further with CT and bronchoscopy to get a clearer diagnosis and guide appropriate treatment.
Any thoughts?
Best regards,
ScottHello again!
I wanted to share a summary of a recent multicenter study on bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, used for alleviating pain associated with osteoarthritis (OA) in dogs. I’ve highlighted the side effects section for your reference.
Study Overview
Objective: Evaluate the efficacy and safety of bedinvetmab in dogs with OA.
Design: Double-blind, randomized, multicenter, placebo-controlled study.
Participants: 287 client-owned dogs with OA.
Methods
Dogs were randomized to receive either a placebo (saline, n = 146) or bedinvetmab (0.5-1.0 mg/kg, n = 141) administered monthly. After three months, dogs that responded positively to bedinvetmab continued to receive the treatment in an open-label phase.Results
Efficacy:Treatment success was significantly higher in the bedinvetmab group compared to the placebo group from day 7 through all assessed time points.
By day 28, 43.5% of dogs treated with bedinvetmab achieved treatment success compared to 16.9% in the placebo group (p = 0.0017).
This success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group, with less than 25% success in the placebo group.
Sustained efficacy was demonstrated in the continuation phase.
Safety:Adverse health events (AHEs) occurred at similar frequencies in both the bedinvetmab and placebo groups and were typical for a population of dogs with OA, often associated with comorbidities.
The most frequently reported AHEs were musculoskeletal disorders, including joint pain and lameness, with joint pain being more common in the placebo group.
During the study, two dogs in the placebo group and one dog in the bedinvetmab group died, but the deaths were not related to the study treatment.
Common AHEs included digestive tract disorders, systemic disorders, skin disorders, and respiratory tract disorders, with some variations between the placebo and bedinvetmab groups.
A mild transient injection site reaction was observed in one dog in each group, complicated by underlying pre-existing atopy.Conclusions
The study demonstrated the effectiveness and safety of bedinvetmab administered monthly for up to nine months at 0.5-1.0 mg/kg for alleviating pain associated with canine osteoarthritis.Side Effects Highlight
Musculoskeletal disorders: Joint pain and lameness were reported, with joint pain more common in the placebo group.
Digestive tract disorders: Emesis and diarrhea were noted.
Systemic disorders: Lethargy and anorexia were observed.
Skin and appendages disorders: Alopecia and pruritus were reported.
Respiratory tract disorders: Cough and tachypnea occurred.
Renal and urinary disorders: Polyuria and urinary incontinence were observed.
Neurological disorders: Proprioception abnormality and paresis were reported but were not common.Just some more evidence to share with clients!
Best,
Scott 🙂
Hi Rosanna,
Welcome back to practice! The concerns about Librela (bedinvetmab) and Solensia (frunevetmab) are understandable given recent reports, and it’s important to balance these concerns with evidence-based information.
Evidence and Known Side Effects
There have been some reports of adverse effects, including nerve problems, in animals receiving these treatments. However, these cases represent a very small percentage of the total number of animals treated with these drugs. A clinical trial involving 287 dogs treated with bedinvetmab showed significant pain relief from osteoarthritis (OA) with minimal adverse effects. Similarly, frunevetmab has shown to be effective in managing OA pain in cats with generally mild and manageable side effects.Advising Clients
When discussing these medications with clients, transparency is key. Inform them of the potential for adverse effects but also emphasize the benefits observed in the majority of patients. It’s important to communicate that while adverse reactions can occur with any medication, the overall safety profile of Librela and Solensia remains positive.Specific Animals to Avoid
There isn’t definitive evidence pointing to a specific subset of animals that are more prone to adverse effects from these drugs. Generally, these medications are used in older animals who are more likely to have multiple health issues. Close monitoring is essential, particularly in animals with pre-existing conditions or those who are immunocompromised.Common Nerve Effects
The nerve effects reported include vestibular signs such as ataxia and head tilt, as well as lethargy and decreased appetite. In most cases, these signs are reversible upon discontinuation of the drug. It’s important to monitor for any signs of adverse reactions and adjust treatment as needed.Treatment and Management
If adverse effects occur, discontinuation of the drug usually leads to resolution of symptoms. Supportive care, such as anti-nausea medication and appetite stimulants, can help manage symptoms in the interim.Further Information
I have some contacts at Zoetis that I will reach out to for more detailed information. Additionally, I plan to consult with some of my anesthesia colleagues to get their input on managing these potential side effects. I’ll be sure to share relevant papers and findings here as well.I look forward to hearing everyone’s comments and experiences with these medications.
Best,
Scott 🙂
Replying to Rodolfo L. 28/06/2024 - 09:30
Hi Rodolfo,
Thank you so much for your kind words! It’s been a pleasure to have you onboard and to see your engagement throughout.
Warm regards,
Scott 🙂
Replying to Rosanna Vaughan 29/06/2024 - 21:26
Hi Rosanna,
I’m glad to hear you’re enjoying Ettinger’s textbook! For quick references that are handy on-the-go, I recommend the following:
BSAVA Manual of Canine Practice: This manual covers a wide range of topics with practical guidance for everyday clinical practice in dogs.
BSAVA Manual of Feline Practice: Similarly, BSAVA’s manual for feline practice provides concise information tailored to cat care.
Notes on Canine Internal Medicine by Victoria L. Black et al.: This book is excellent for quick insights into various aspects of internal medicine in dogs.
Happy reading!
Best regards,
Scott
Replying to Ursula Lanigan 23/06/2024 - 22:25
Great question!
I will see if Neus and Felipe have any further comments!
Scott 🙂
Replying to Janette B. 24/06/2024 - 08:59
Hi Janette,
Great to see you again! Thanks for continuing to work with us. Your expertise in Anaesthesia and Analgesia is incredibly valuable, and I’m looking forward to your whirlwind tour. There’s indeed so much to learn and discuss.
Best regards,
Scott 🙂
Replying to Matteo R. 27/06/2024 - 12:12
Hi Matteo,
Great to see you here! Your work in small animal surgery, particularly with open-heart surgery for mitral valve repair and congenital heart conditions, sounds incredibly cool. I’m looking forward to your lecture and the tips and tricks you have to offer.
Best regards,
Scott 🙂
-
AuthorPosts